Humanetics gets financing from NIAID to study BIO 300 drug in Covid-19 patients

This article was originally published here

NIAID is part of the National Institutes of Health, which is an agency of the US Department of Health and Human Services. The trial will target patients who

The post Humanetics gets financing from NIAID to study BIO 300 drug in Covid-19 patients appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply